Table 3.

Immediate impact of Universal Coverage Scheme on hospital sector market share*

Therapeutic area	Licensing status	Immediate postpolicy absolute change in % market share (95% CI)
Diabetes
Antidiabetics	Originator brand	−0.3% (−1.6 to 1.0)
	Branded generic	−12.3% (−16.0 to −8.7)*
	Generic	−3.5% (−5.8 to −1.1)*
	GPO	16.1% (12.0 to 20.2)*
Insulins‡	Originator brand†	−0.04% (−0.4 to 0.3)
	Branded generic	7.0% (2.9 to 11.1)*
	Generic	−6.2% (−10.3 to −2.1)*
Cardiovascular disease
Antihypertensives	Originator brand†	−0.1% (−2.3 to 2.0)
	Branded generic†	−0.2% (−6.1 to 1.8)
	Generic	−5.7% (−8.3 to −3.0)*
	GPO	5.3% (−0.1 to 10.6)
Lipid regulating agents	Originator brand†	−7.8% (−10.2 to −5.4)*
	Branded generic†	7.6% (5.1 to 10.0)*
	Generic	0.2% (−0.4 to 0.7)
	GPO	0.2% (−0.3 to 0.8)
Cardiac therapy	Originator brand	0.1% (−0.8 to 1.0)
	Branded generic†	−13.5% (−20.5 to −6.5)*
	Generic	−4.3% (−6.2 to −2.4)*
	GPO	21.6% (15.0 to 28.1)*
Cancer‡
Antineoplastics	Originator brand	1.1% (−1.0 to 3.2)
	Branded generic	−1.0% (−5.4 to 3.4)
	Generic	0.4% (−2.7 to 3.4)
Cytostatic hormones	Originator brand†	0.4% (−5.4 to 6.1)
	Branded generic†	−7.7% (−12.0 to −3.5)*
	Generic†	6.0% (1.4 to 10.6)*
Immunostimulating agents	Originator brand	−6.4% (−9.7 to −3.0)*
	Branded generic	4.5% (1.7 to 7.3)*
	Generic	−0.2% (−0.3 to 0.02)

*Statistically significant regression coefficient (p<0.05). Changes are in absolute terms (ie, percentage point change).

†Quadratic model (which has a squared postpolicy trend term) fits better than linear model.

‡GPO did not produce any insulins or cancer medicines during the study period.

Note 1: See online appendix table 4 and figures 9–16 for market share regression coefficients and figures for all therapeutic areas.

Note 2: Aside from the immediate level changes following the policy, there were few major changes in market share. See online appendix table 5 for absolute 1- and 5-year differences.